Recombinant activated factor VII for uncontrolled bleeding postcardiac surgery

Area of Science:

• Cardiology
• Hematology
• Surgical Critical Care

Background:

• Persistent hemorrhage after cardiac surgery poses significant risks.
• Conventional treatments may not always suffice for severe bleeding.
• Recombinant activated factor VII (rFVIIa) is a potential therapeutic option.

Purpose of the Study:

• To evaluate the safety and efficacy of rFVIIa in managing persistent hemorrhage post-cardiac surgery.
• To compare outcomes between patients receiving rFVIIa and those receiving conventional treatment.

Main Methods:

• Retrospective observational study design.
• Two groups: control (conventional treatment) and rFVIIa (conventional treatment + rFVIIa).
• Inclusion criteria: bleeding ≥ 3 ml/kg/h for 2 consecutive hours post-cardiac surgery.

Main Results:

• rFVIIa significantly decreased chest tube output at 4 and 9 hours post-CSICU admission compared to controls.
• Fewer blood products were transfused in the rFVIIa group (3-12 hours post-CSICU).
• Reexploration rates were lower in the rFVIIa group (p=0.01), but Thromboembolic Adverse Events (TAE) showed no significant difference (p=0.27).

Conclusions:

• rFVIIa successfully reduced chest tube bleeding and blood product transfusion in severe post-cardiac surgical bleeding.
• The safety of rFVIIa in this context remains uncertain.
• Further prospective controlled trials are necessary to confirm the role and safety of rFVIIa.